RxDoctor Payments DataLook up a doctor →

Elizabeth Berger, PA

Physician Assistant · Great Bend, KSNPI 1962059873

Payments from drug & device makers

$7,924in general payments, 2019–2025

Across 454 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$605
  • AstraZeneca$560
  • Johnson & Johnson$550
  • GSK$451
  • Sanofi$410
  • Tersera Therapeutics LLC$403
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,57196%
  • Education$3534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis47$605
AstraZeneca27$560
Johnson & Johnson33$550
GSK33$451
Sanofi20$410
Tersera Therapeutics LLC15$403
Genentech USA, Inc.25$377
Takeda Pharmaceuticals U.S.A., Inc.17$323
Gilead(2 entities)16$289
Pfizer25$245
Jazz Pharmaceuticals Inc.13$227
Daiichi Sankyo Inc.10$219
AbbVie10$202
Incyte Corporation12$199
Bristol Myers Squibb12$197
Sobi, Inc10$192
Exelixis Inc.6$184
Regeneron Healthcare Solutions, Inc.6$172
Bayer9$155
Stemline Therapeutics Inc.9$142
Seagen Inc.2$105
Ipsen Biopharmaceuticals, Inc6$104
Sumitomo Pharma America, Inc.5$93
Organon5$87
E.r. Squibb & Sons, L.L.C.5$82
Lilly USA, LLC4$80
Apellis Pharmaceuticals, Inc.4$78
Astellas Pharma US Inc4$66
Iovance Biotherapeutics, Inc.4$65
Spectrum Pharmaceuticals Inc.4$60
Pharmacosmos Therapeutics Inc.4$60
EMD Serono, Inc.3$59
Pharmacyclics LLC, An Abbvie Company3$56
Taiho Oncology, Inc.3$51
Springworks Therapeutics, Inc.3$49
Adaptive Biotechnologies Corporation2$48
Array Biopharma Inc2$45
CTI Biopharma Corp.3$45
Blueprint Medicines Corporation3$45
Genmab U.S., Inc.2$44
Acceleron Pharma, Inc.3$41
Mylan Institutional Inc.2$41
Puma Biotechnology, Inc.2$36
AVEO Pharmaceuticals, Inc.2$35
Boehringer Ingelheim1$27
Kyowa Kirin, Inc.1$24
Geron Corporation1$24
Merck1$24
Dova Pharmaceuticals1$19
Immunocore Limited1$19
Blue Earth Diagnostics1$19
Boston Scientific1$18
Azurity Pharmaceuticals, Inc.1$18
Recordati_rare_diseases_inc.1$17
Amgen1$17
Acrotech Biopharma Inc.1$16
Karyopharm Therapeutics Inc.1$16
Servier Pharmaceuticals LLC1$16
Myriad Genetic Laboratories, Inc.1$16
Dendreon Pharmaceuticals LLC1$15

How this compares

$7,924 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$74,418
Medicare patients
400
Services billed
1,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Potassium Chloride21$430
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$333
Hydrocortisone13$301
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$185
Olanzapine13$113
Acyclovir29$98
Azithromycin20$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$80$11313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Great Bend

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →